Experimental tumor injection trial halted early
NCT ID NCT03871348
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced solid cancers like melanoma. However, the trial was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR441000 (injected into tumors) and cemiplimab (given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) trial that was terminated, so results are limited. The approach is experimental and may not prove safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic - Cleveland- Site Number : 8400007
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute- Site Number : 8400003
Boston, Massachusetts, 02215, United States
-
Investigational Site Number : 0560001
Brussels, 1200, Belgium
-
Investigational Site Number : 0560002
Leuven, 3000, Belgium
-
Investigational Site Number : 0560003
Ghent, 9000, Belgium
-
Investigational Site Number : 2500001
Villejuif, 94805, France
-
Investigational Site Number : 2500002
Paris, 75010, France
-
Investigational Site Number : 2500004
Marseille, 13885, France
-
Investigational Site Number : 2760001
Mainz, 55131, Germany
-
Investigational Site Number : 2760003
Mannheim, 68167, Germany
-
Investigational Site Number : 2760004
Heidelberg, 69120, Germany
-
Investigational Site Number : 2760005
Hamburg, 20246, Germany
-
Investigational Site Number : 2760006
Tübingen, 72076, Germany
-
Investigational Site Number : 5280001
Rotterdam, 3015 CE, Netherlands
-
Investigational Site Number : 5280002
Nijmegen, 6525 GA, Netherlands
-
Investigational Site Number : 7240001
Pamplona, Navarre, 31008, Spain
-
Investigational Site Number : 7240002
Valencia, 46014, Spain
-
Investigational Site Number : 7240004
Barcelona, Catalunya [Cataluña], 08036, Spain
-
The University of Texas MD Anderson Cancer Center- Site Number : 8400002
Houston, Texas, 77030, United States